• Home
  • Solutions
    ProductsPlatformIngest EngineServicesDemo Room
  • Resources
    News & ViewsCase StudiesEventsFAQs
  • About
    About UsThe Way We WorkThe Team
  • Contact
    Book a DemoRequest InformationContact Us
Sign In Book a Demo
May 6, 2019 posted in Articles
1 min read

What the FDA Says

These documents are either from or about the FDA and its concerns about clinical trials. What’s more important is that the concerns addressed within these articles can all be addressed with the capabilities of the Remarque Systems Platform.

  • Speech Transforming FDAs Approach to Digital Health
  • FDA Draft RBM monitoring
  • FDA Seeks More Efficent Clinical Research Strategies to Lower Drug Costs

Subscribe to Our Blog. Stay up to date with the latest news and insights.

Earlier news: Technology: Friend or Foe – Considerations for Practical Execution of a Risk-Based Monitoring (RBM) Strategy
Newer news: Making Risk-Based Monitoring Technology a Friend: Considerations for Practical Execution of an RBM Strategy
  • Contact Us
  • About Us
  • FAQs
  • Careers
  • Terms & Conditions
  • Remarque Systems Privacy Policy
  • LinkedIn
  • Twitter
  • Vimeo
  • YouTube
© 2023 Remarque Systems. All rights reserved.